This article will revise the novel treatment of two conditions that lead to hypophosphatemia with high FGF-23 levels: tumor-induced osteomalacia (TIO) and X-linked hypophosphatemic rickets (XLH). This evidence concerns the gene FGF23 and X-linked hypophosphatemia.